TIMP3 and diabetes mellitus: Pharmacological inhibition of ADAM17 led to an amelioration of the pathology, thus indicating that TIMP-3 links the interplay between reduced insulin action and aberrant ADAM17 activity in diabetes and vascular inflammation [87].